Alnylam Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALNY Alnylam Pharmaceuticals Inc
NUV Nuveen Municipal Value Fund
NNBR NN Inc
WAT Waters Corp
ADP Automatic Data Processing Inc
CLABF Core One Labs Inc
FRHLF Freehold Royalties Ltd
WDAY Workday Inc
ENVX Enovix Corp
ENB Enbridge Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.

Closing Price
$148.50
Day's Change
0.50 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
152.42
Day's Low
142.69
Volume
(Light)
Volume:
457,129

10-day average volume:
740,048
457,129

Vornado Declares Quarterly Dividends On Preferred Shares

3:38 pm ET October 28, 2021 (Globe Newswire) Print

Vornado Realty Trust (NYSE:VNO) announced today that its Board of Trustees has declared the following quarterly preferred dividends:

Series A Convertible           $ .8125000 per share
Series L Cumulative Redeemable $ .3375000 per share
Series M Cumulative Redeemable $ .3281250 per share
Series N Cumulative Redeemable $ .3281250 per share
Series O Cumulative Redeemable $ .3059375 per share

The Series O dividend includes $.0278125 per share from September 22, 2021 (settlement date) through September 30, 2021.

In each case, dividends are payable on January 3, 2022 to shareholders of record on December 15, 2021.

Vornado Realty Trust is a fully-integrated equity real estate investment trust.

CONTACT

Thomas Sanelli

(212) 894-7000

Certain statements contained herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of factors that could materially affect the outcome of our forward-looking statements and our future results and financial condition, see "Risk Factors" in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2020. Such factors include, among others, risks associated with the performance of the Company's properties and general competitive factors. Currently, one of the most significant factors is the ongoing adverse effect of the COVID-19 pandemic on our business, financial condition, results of operations, cash flows, operating performance and the effect it has had and may continue to have on our tenants, the global, national, regional and local economies and financial markets and the real estate market in general. The extent of the impact of the COVID-19 pandemic will depend on future developments, including the duration of the pandemic, current and future variants, the efficacy and durability of vaccines against the variants and the potential for increased government restrictions, which continue to be uncertain at this time but that impact could be material. Moreover, you are cautioned that the COVID-19 pandemic will heighten many of the risks identified in "Item 1A. Risk Factors" in Part I of our Annual Report on Form 10-K for the year ended December 31, 2020.

https://ml.globenewswire.com/media/efbaefe0-e132-48f3-8bcd-98381375ee14/small/vno-rt-logo-black-04-28-2015-jpg.jpg

https://ml.globenewswire.com/media/efbaefe0-e132-48f3-8bcd-98381375ee14/small/vno-rt-logo-black-04-28-2015-jpg.jpg

comtex tracking

COMTEX_395976671/2010/2021-10-28T15:38:18

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.